Dr. Mariola Söhngen,
Chief Executive Officer (CEO)
is responsible for Strategy, Partnering, Business Development, Research, Production as well as Investor Relations and Corporate Communications.
Dr Mariola Söhngen has acquired a wealth of experience in the biotechnological and pharmaceutical industry. She is co-founder of both PAION AG and PAION Deutschland GmbH and served as a Managing Director since the foundation. In addition, from 2004 to 2015 she held the position of Chief Medical Officer (CMO) of PAION AG. In this function she was responsible for clinical drug development Phase I-IV, Regulatory, Drug Safety, Quality Assurance and other areas.
Until the foundation of PAION she worked for globally operating pharmaceutical companies Grünenthal GmbH and Ferrer Internacional S.A. (its subsidiary Trommsdorf GmbH & Co. KG Arzneimittel ). There she was responsible for Project Coordination, Licencing, Strategic Project Evaluation and Interfacing with Marketing. In 1998 she founded her own company, Bootcamp, which prepared entrants in the job market for professions in the healthcare industry.
Following her medical degree in 1987, Dr Söhngen obtained both a PhD in Medicine (1988), a Diploma in Pharmaceutical Medicine (DGPharMed, 1996) and Master of Business Communication (1999).
Dr Mariola Söhngen joined the Executive Board of MOLOGEN AG in November 2015.
She acts as member of the Supervisory Board of Vita 34 AG, Leipzig.
Chief Financial Officer (CFO)
Responsible for Finance and Administration, Human Resources, Risk Management, Compliance and Corporate Governance as well as Legal and IT.
Walter Miller has more than 15 years of experience in the biotech and pharmaceutical industry, in both startups and listed companies. In 2013, he became the authorized signatory and commercial director (CFO) of Nuvisan GmbH, Germany, an international contract research organization (CRO) and laboratory service provider, where he assumed responsibility for the commercial and administrative areas of the company. Prior to this, between 2002 and 2013, he held various management positions in the Santhera Pharmaceuticals Group, initially in Germany and later in Switzerland, most recently as Vice President Finance & Commercial Operations and as a Member of the Executive Board. In particular, his remit included the development of the organization, the accounting system and project controlling as well as handling strategic financial matters and in- and out-licensing activities. Furthermore, he was significantly involved in the cross-border merger, the initial public offering (IPO) on the SIX Swiss Exchange and various financing deals.
Before entering the biotech and pharmaceutical industry, Walter Miller’s last position was as Head of Accounting and Controlling at Parsytec AG, Germany. In this role, his responsibility covered the Group’s international consolidated financial statements in accordance with US-GAPP, project controlling and the finances of foreign subsidiaries. In addition, he was on the IPO team in 1999.
Walter Miller obtained his qualification for Business Administration in Aachen, Germany, in 1997. He was also awarded a Baccalaureate in the Science of Marriage and Family in 1994 (comparable with a Bachelor of Arts) and the Controller’s Diploma at the Controller Akademie Gauting, near Munich, in 2004.
In April 2016, Walter Miller became the new Chief Financial Officer of MOLOGEN AG.
Walter Miller currently does not hold any other board memberships.